Navigation Links
CV Therapeutics Reports 2008 First Quarter Financial Results
Date:4/25/2008

expenses and lower general and administrative costs offset in part by higher personnel-related expenses.

The decrease in costs and expenses in the quarter ended March 31, 2008 compared to the same quarter in 2007 was primarily due to a reduction in personnel-related expenses related to the restructuring plan implemented in May 2007, lower research and development expenses resulting from lower clinical trial expenses related to the completion of the MERLIN TIMI-36 study of Ranexa and lower regadenoson research and development expenses, and lower Ranexa marketing and sales expenses. These decreases were partially offset by higher cost of sales due to higher net product sales of Ranexa.

At March 31, 2008, the Company had cash, cash equivalents, marketable securities and restricted cash of $151.0 million compared to $179.0 million at December 31, 2007. Our cash utilized for the quarter ended March 31, 2008 was $28.0 million. This compares to our cash utilized for the prior quarter of $20.5 million. The increase in cash utilization in the quarter end March 31, 2008 compared to the prior quarter was due primarily to the timing of certain compensation and payroll related tax payments.

In April 2008, we announced that TPG-Axon Capital agreed to pay CV Therapeutics up to $185.0 million in exchange for rights to 50 percent of our royalty on North American sales of Lexiscan(TM) (regadenoson) injection. We received $175.0 million on closing of the transaction in April 2008 and could receive a potential future milestone payment of $10.0 million. We also received a $12.0 million milestone payment from Astellas US LLC in connection with the FDA approval of Lexiscan(TM) in April 2008.

Company management will webcast a conference call on April 25, 2008 at 8:30 a.m. EDT, 5:30 a.m. PDT, on the Company's website. To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to t
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2
... - Company to Host Conference Call at 4:30 p.m. ET ... PCYC ) today reported financial results for its fourth ... for the fourth quarter of,fiscal 2008 was $4.6 million, or ... or $0.27 per share, for the fourth quarter of fiscal ...
... is accelerating improvements for converting plant biomass into biofuelas ... needs, reports Eddy Rubin, Director of the U.S. Department ... August 14 edition of the journal Nature . ... a path forward for how emerging genomic technologies will ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... leading proxy advisory firms, have,recommended that SGX stockholders vote ... LLY ) at the SGX Special Stockholders Meeting,scheduled ... The Board of Directors of SGX unanimously recommends ...
Cached Biology Technology:Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... influenza caused widespread death and illness in 1918, 1957, 1968 ... time of these pandemics finds that each of them was ... study,s authors--Jeffrey Shaman of Columbia University,s Mailman School of Public ... Healthnote that the La Nia pattern is known to alter ...
... new varieties of corn with a higher yield faster than ... Germany, and other institutions are relying on a trick: early ... chemical and genetic makeup, as well as on new statistical ... authoritative journal Nature Genetics on Sunday evening, Jan. ...
... proteins have characteristic ways of "walking," which (also like human ... have discovered the unique "drunken sailor" gait of dynein, a ... in the body and whose malfunction has been associated with ... The research, which was led by Samara Reck-Peterson ...
Cached Biology News:Does the La Niña weather pattern lead to flu pandemics? 2Good parents are predictable -- at least when it comes to corn 2Good parents are predictable -- at least when it comes to corn 3Good parents are predictable -- at least when it comes to corn 4Walk this way: Scientists and MBL physiology students describe how a motor protein 'steps out' 2
... the principal excitatory neurotransmitter receptors ... glutamate receptors exist: Ionotropic receptors, ... receptors are oligomeric complexes of ... which comprise ligand-gated calcium channels. ...
Recommended fro Western blotting application...
... KLF15 is a Cys2-His2 zinc finger gene. ... liver, kidneys, heart, and skeletal muscle. ... produced in rabbits immunized with a synthetic ... KLF15 with an internal ID of P03590 ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
Biology Products: